Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.
Milestone Pharmaceuticals Inc. develops and commercializes cardiovascular medicines, centered on CARDAMYST (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also being developed for symptomatic episodic attacks associated with AFib-RVR.
Company news commonly covers CARDAMYST commercialization, payer formulary access, real-world evidence work such as the RESET-PSVT registry, cardiovascular conference presentations, regulatory updates, financial results and business updates. Milestone also reports equity inducement grants and other corporate actions tied to its Nasdaq-listed common shares.
Milestone Pharmaceuticals (Nasdaq:MIST) announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, in New York.
A live and replay webcast of the 3:00 p.m. ET fireside chat will be available on Milestone's website.
Milestone Pharmaceuticals (Nasdaq:MIST) reported first quarter 2026 results and a corporate update. CARDAMYST™ nasal spray for PSVT is ramping, with about 600 scripts for 560 patients and roughly 400 unique prescribers through April. Express Scripts added CARDAMYST to its national formularies, giving coverage to over 25% of commercially insured U.S. lives. The company initiated a Phase 3 registration trial of etripamil for AFib-RVR, with first patient enrollment expected in H2 2026, and advanced global expansion with an EMA MAA under review and a China NDA accepted. Q1 product revenue was $0.2 million. Cash, cash equivalents and short-term investments totaled $184.2 million, which Milestone expects will fund operations into H2 2027. Net loss was $26.1 million, or $0.20 per share.
Milestone Pharmaceuticals (Nasdaq: MIST) will report first quarter 2026 financial results on May 13, 2026 before the market open and will host a conference call and webcast at 8:30am ET.
Investor dial-in numbers, conference ID 13760062, and a webcast replay will be available on Milestone's website.
Milestone (Nasdaq: MIST) announced RESET-PSVT, a planned Phase 4, multicenter, prospective, observational registry to generate real-world evidence on CARDAMYST (etripamil) nasal spray in adults with paroxysmal supraventricular tachycardia (PSVT).
The registry, led by the Duke Clinical Research Institute, aims to enroll an estimated 450 patients across ~20 sites, with enrollment beginning by the end of 2026. Primary and secondary endpoints include patterns of use, episode frequency, doses per episode, patient-reported quality of life and healthcare utilization. CARDAMYST received FDA approval in December 2025 and is commercially available in the United States.
Milestone Pharmaceuticals (Nasdaq: MIST) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. Management's webcast is scheduled for April 13, 2026 at 3:45 PM EDT.
According to the company, the presentation webcast will be available April 13 with a replay accessible for approximately 90 days on Milestone's News & Events page. Investors seeking meetings should contact their Needham representative.
Milestone Pharmaceuticals (Nasdaq: MIST) granted a total of 123,000 stock options under its 2021 Inducement Plan as material inducements for three new hires. The options were granted with an April 1, 2026 grant date and an exercise price of $1.31, equal to the closing share price on that date. The options vest over four years (25% after one year, then monthly over 36 months) and are subject to continuous service and the Plan's terms pursuant to Nasdaq Listing Rule 5635(c)(4).
Milestone Pharmaceuticals (Nasdaq: MIST) announced that Express Scripts added CARDAMYST (etripamil) nasal spray to its commercial national formularies, effective March 27, 2026. This inclusion makes CARDAMYST broadly accessible and more affordable for Express Scripts' commercially insured lives across the United States.
CARDAMYST is the first FDA‑approved self‑administered nasal spray for converting acute symptomatic PSVT to sinus rhythm in adults; Milestone said this represents the company's first contracted formulary acceptance by a major payor and expects coverage to expand with additional insurer engagements.
Milestone Pharmaceuticals (Nasdaq: MIST) reported FDA approval and U.S. launch of CARDAMYST (etripamil) nasal spray for acute symptomatic PSVT, with retail availability in late January 2026 and national sales deployment in mid-February 2026. The company reported $106.0 million cash at year-end and pro forma liquidity of about $200 million supporting runway into late 2027.
Full-year 2025 results include $1.5 million revenue, R&D $18.1 million, commercial expense $28.3 million, and a net loss of $63.1 million. EMA MAA accepted with a decision expected by H1 2027.
Milestone (Nasdaq: MIST) will present data at ACC.26 (March 28-30, 2026) showing minimal blood pressure effects after intranasal etripamil (CARDAMYST) test dosing.
Phase 3 analysis reported mean systolic BP change ~1.8 mmHg (single 70 mg, N=440) and TEAE rates of hypotension 0.4% and syncope 0.2% (N=1,610), supporting potential safe self-administration for adults with PSVT.
Milestone Pharmaceuticals (Nasdaq: MIST) will report its fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026 before the market opens. A conference call and webcast for investors is scheduled at 8:30am ET.
Access details include domestic and international dial‑in numbers, a conference ID, a Call me™ option active 15 minutes before start, and a replay available on the company’s Investors and Media website.